Axtle is a drug owned by Avyxa Holdings Llc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 25, 2045. Details of Axtle's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12721811 | NA |
Jun, 2045
(18 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Axtle is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Axtle's family patents as well as insights into
ongoing legal events
on those patents.
Axtle's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Axtle's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 25, 2045 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Axtle Generics:
There are no approved generic versions for Axtle as of now.
About Axtle
Axtle is a drug owned by Avyxa Holdings Llc. Axtle uses Pemetrexed Dipotassium as an active ingredient. Axtle was launched by Avyxa in 2024.
Approval Date:
Axtle was approved by FDA for market use on 28 June, 2024.
Active Ingredient:
Axtle uses Pemetrexed Dipotassium as the active ingredient. Check out other Drugs and Companies using Pemetrexed Dipotassium ingredient
Dosage:
Axtle is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG BASE/VIAL | POWDER | Prescription | INTRAVENOUS |
| EQ 500MG BASE/VIAL | POWDER | Prescription | INTRAVENOUS |